Printer Friendly

Invent Ventures and Heliant Ventures co-invest in Sanguine BioSciences.

INTERNET BUSINESS NEWS-(C)1995-2013 M2 COMMUNICATIONS

Invent Ventures, Inc. (OTC: IDEA) said it has led the seed financing round in Sanguine BioSciences, a biotechnology company empowering patients in biomedical research.

Along with Invent, Heliant Ventures, a VC technology fund, jointly lead the round of investment in Sanguine.

Invent's investment in Sanguine keeps with its strategy of building and investing in evolving and rapidly growing companies. In addition to Sanguine BioSciences, which supplies DNA data and bio-specimen to research organizations for the development of personalized medicines, Invent has also developed Virurl Inc., one of the early pioneers in native advertising. Virurl builds tools and technologies to create native advertising campaigns, and has raised USD1.2M in seed financing to date. Since formation in 2010, Invent has built six technology companies, which have raised over USD3.5M at an aggregate valuation over USD10M, with under USD450K of capital investment.

Invent Ventures is a venture fund that builds and invests in transformative technology businesses. Invent pursues ventures in the consumer Internet, mobile and biotechnology markets, and has built six companies at various stages of development. Invent is headquartered in Santa Monica, California. For more information on Invent, visit www.invent.vc.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDMarch 11, 2013>JNINTERNET BUSINESS NEWS.PRICEDATENOT APPLICABLE.DAY
COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Internet Business News
Date:Mar 11, 2013
Words:221
Previous Article:Aurasma passes 16,000 customer milestone.
Next Article:NetApp Data ONTAP picked as best branded storage operating system.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters